InvestorsHub Logo
Followers 7
Posts 631
Boards Moderated 0
Alias Born 09/23/2014

Re: Investor2014 post# 339339

Thursday, 12/09/2021 3:41:55 PM

Thursday, December 09, 2021 3:41:55 PM

Post# of 462977
Trials evaluating muscarinic receptors have failed based safety profile, and interestingly have shown improvements in CNS endpoints. Sigma 1 has been the subject of many trials, generally well tolerated and shown clinical benefit in other CNS areas.

The publication referencing Tanzi's work didn't align with other research.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News